The first-in-human HEART-1 trial of in vivo DNA editing called VERVE-101, shows reductions in LDL and PCSK9 protein in patients with familial hypercholesterolemia.
The new cardiovascular disease risk equations start at age 30, include measures of kidney and metabolic health, add heart failure, and remove race from the equations.
For 1 in 4 patients with primary biliary cholangitis (PBC) who received the investigational PPAR-delta agonist, alkaline phosphatase levels normalized.
The prevalence of elevated low-density lipoprotein cholesterol has declined recently, but millions of Americans still have levels for which treatment is recommended or should be considered and many remain untreated.